{"protocolSection":{"identificationModule":{"nctId":"NCT06476899","orgStudyIdInfo":{"id":"PragmatiCLL"},"organization":{"fullName":"The First Affiliated Hospital of Nanchang University","class":"OTHER"},"briefTitle":"A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy","officialTitle":"A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy in Previously Untreated CLL/SLL"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07-24","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-03-26","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12-26","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-19","studyFirstSubmitQcDate":"2024-06-21","studyFirstPostDateStruct":{"date":"2024-06-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-21","lastUpdatePostDateStruct":{"date":"2024-06-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Fei Li","investigatorTitle":"Chief physician","investigatorAffiliation":"The First Affiliated Hospital of Nanchang University"},"leadSponsor":{"name":"Fei Li","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Prospective, interventional, and practical clinical studies"},"conditionsModule":{"conditions":["CLL/SLL"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"OTHER","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":60,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Fixed regimen","type":"EXPERIMENTAL","description":"orelabrutinib + FCR/BR","interventionNames":["Drug: orelabrutinib","Drug: FCR/BR"]},{"label":"Control","type":"ACTIVE_COMPARATOR","description":"BTKi chosen by doctors","interventionNames":["Drug: BTK inhibitor"]}],"interventions":[{"type":"DRUG","name":"orelabrutinib","description":"orelabrutinib tablets","armGroupLabels":["Fixed regimen"]},{"type":"DRUG","name":"FCR/BR","description":"FCR/BR","armGroupLabels":["Fixed regimen"]},{"type":"DRUG","name":"BTK inhibitor","description":"BTK inhibitor choose by physican","armGroupLabels":["Control"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"TTNTD rate at 30 months","description":"The proportion of time from the start of treatment to the start of the next treatment or death over a period of 30 months","timeFrame":"30 months"}],"secondaryOutcomes":[{"measure":"PFS","description":"The time from the start of treatment to the point when the disease progression or death is confirmed by the investigator","timeFrame":"3 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age between 18 and 70 years, with no gender restrictions;\n* Patients with CLL/SLL who meet the iwCLL2018 diagnostic criteria;\n* Indications for treatment\n* ECOG performance score of 0-2;\n* Patients are untreated or have not received standardized treatment\n* Before the trial screening, the subject or their legal representative voluntarily signs a written informed consent form, indicating that they understand the purpose of the study and the necessary research steps, and are able to comply with the protocol and follow-up.\n\nExclusion Criteria:\n\n* Has been diagnosed or treated for malignancies other than CLL (including active central nervous system lymphoma) within the past year;\n* there is clinical evidence of Richter transformation;\n* Participant cannot receive or plan to receive another treatment during study participation\n* Other conditions that the investigator considers inappropriate for participation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"}},"hasResults":false}